India Antimalarial Drugs Market

India Antimalarial Drugs Market, By Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Others), By Mechanism of Action (Treatment for Malaria, Prevention from Malaria), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Region, Competition Forecast & Opportunities, 2018-2028F

India Antimalarial Drugs Market is expected to grow steadily between 2024 and 2028, with an impressive CAGR. This can be attributed to the high prevalence of malaria, rising healthcare expenditure and increasing research & development activities.

India has been a global leader in the production of generic medicines, including antimalarial drugs, for decades. With malaria being a major public health challenge in the country, there has been a consistent demand for effective antimalarial drugs.

The presence of a high number of pipeline items regarding antimalarial drugs in India is also positively influencing the growth of the antimalarial drug market in the country. Plasmodium falciparum, P. vivax, P. ovale, and P. malariae are the four types of malaria parasites that affect people, according to the US-based Centre for Disease Control and Prevention.

The Indian government has implemented several initiatives to combat malaria, including the National Vector Borne Disease Control Program. The program focuses on preventing and controlling vector-borne diseases such as malaria, dengue, and chikungunya. The government has also implemented policies to encourage the production of generic drugs, which has helped to increase the availability and affordability of antimalarial drugs in the country, thereby driving the growth of India Antimalarial Drugs Market.

Indian pharmaceutical companies are increasingly investing in research and development to develop new and more effective antimalarial drugs. The government's support for innovation in the healthcare sector is further driving R&D investment. This is expected to result in the development of new drugs that are more effective against drug-resistant strains of malaria, thereby creating lucrative opportunities for the growth of India antimalarial drugs market in the next few years.

There is a growing focus on preventive healthcare in India, with people increasingly seeking to prevent illnesses rather than just treating them. This has led to an increase in demand for preventive measures, including antimalarial drugs. The trend towards preventive healthcare is expected to support the growth of the India antimalarial drugs market in the coming years.

India has strong partnerships with several international organizations, including the World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria. These partnerships have helped to increase access to antimalarial drugs in India and other countries where malaria is endemic. Furthermore, these partnerships are expected to drive further research and development, helping to develop more effective drugs against drug-resistant strains of malaria, thereby fueling the growth of India Antimalarial Drugs Market.

Several factors are impeding the growth of India Antimalarial Drugs Market. These factors include poor healthcare infrastructure, lack of awareness, competition from counterfeit drugs, and pricing pressures. Drug resistance is a major problem in the treatment of malaria, and it is a growing concern in India. There are several drug-resistant strains of malaria, which makes it difficult to treat the disease effectively. This has led to a significant decrease in the effectiveness of some antimalarial drugs, and in turn, has led to a decrease in demand for these drugs.

Rising Prevalence of Malaria in India

The rising prevalence of malaria in India is undoubtedly influencing the growth of antimalarial drugs in the country. Malaria is a major public health problem in India, and its prevalence has been increasing over the past few years. This has led to an increased demand for effective and affordable antimalarial drugs in the country. According to WHO, World Malaria Report 2022, India accounted for 79% of malaria cases in the South East Asia region and about 83% of all malaria deaths in the WHO South-East Asia Region. The Indian pharmaceutical industry has responded to this demand by investing in research and development of new antimalarial drugs. Several Indian pharmaceutical companies have developed and marketed various antimalarial drugs that are affordable and accessible to the people in need. These drugs have been developed using indigenous technology and expertise, and they have helped in addressing the increasing demand for antimalarial drugs in the country. Furthermore, the Indian government has also initiated various programs and schemes to provide free or subsidized antimalarial drugs to the people in need, particularly in the rural areas. These programs and schemes have helped in improving the accessibility and affordability of antimalarial drugs in the country.

Moreover, the regulatory framework for drug development and approval in India is still evolving and can be challenging for new drug development. The lack of clear regulatory guidelines and processes can make it difficult for companies to obtain approvals for new drugs, which can slow down the growth of the antimalarial drug market in India.

Increasing R&D Activities

The increasing research and development (R&D) activities regarding antimalarial drugs in India are positively influencing the growth of the antimalarial drug market in the country. The R&D activities have led to the development of new drug molecules and formulations, which have shown promising results in clinical trials. According to clinicaltrials.gov, there are around 32 studies related to antimalarial drugs which are in different phases of development in India. This in turn will bring a lot of new drugs into the market in the coming years. These new drugs are expected to provide better treatment outcomes, reduce drug resistance, and increase patient compliance.

Furthermore, the R&D activities have also led to the development of novel drug delivery systems and technologies, such as liposomal drug delivery systems and nano-formulations, which can improve the efficacy and safety of antimalarial drugs. Moreover, the Indian government has been supporting R&D activities in the field of antimalarial drugs through various initiatives and schemes. The government has established research institutions and laboratories, such as the National Institute of Malaria Research (NIMR) and the Central Drug Research Institute (CDRI), which are engaged in R&D activities to develop new antimalarial drugs. All these factors are expected to support the growth of India antimalarial drugs market in the forecast period.

Presence of High Number of Pipeline Items

The presence of a high number of pipeline items regarding antimalarial drugs in India is influencing the growth of the antimalarial drug market in the country. The Indian pharmaceutical industry has a robust pipeline of antimalarial drugs in various stages of development, ranging from pre-clinical to clinical trials.

The high number of pipeline items indicates the growing interest of the Indian pharmaceutical industry in the development of new antimalarial drugs. It is also an indication of the increasing investment in research and development activities in the field of antimalarial drugs in India.

Moreover, the presence of a high number of pipeline items indicates the potential for innovation in the antimalarial drug market in India. The pipeline items include novel drug molecules, drug delivery systems, and technologies that can improve the efficacy and safety of antimalarial drugs.

Furthermore, the high number of pipeline items is expected to increase competition in the antimalarial drug market in India. The competition can lead to better quality drugs, lower prices, and increased accessibility of antimalarial drugs to the people in need.

Market Segmentation

India Antimalarial Drugs Market can be segmented by drug class, by mechanism of action, by distribution channel and by region. Based on drug class, the India Antimalarial Drugs market can be divided into Aryl aminoalcohol compounds, Antifolate compounds, Artemisinin compounds, and Others. Based on Mechanism of action, the India Antimalarial Drugs market is divided into Treatment for Malaria and Prevention from Malaria. Based on distribution channel, the market is divided into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. In terms of regions, India Antimalarial Drugs market can be categorized into North, South, East and West.

Market Players

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Strides Pharma Science Ltd, Ipca Laboratories Ltd, Aurobindo Pharma Ltd, Alkem Laboratories Ltd, Novartis India Ltd, Lupin Limited, Cadila Healthcare Ltd is some of the leading players operating in the India Antimalarial Drugs Market. Various companies operating in the market are following different strategies to stay competitive and have an edge over the other players operating in the India Antimalarial Drugs Market. For instance, Novartis and Medicines for Malaria Venture (MMV) have announced their decision to move forward with a Phase 3 study for a novel combination of ganaplacide and lumefantrine-SDF in adults and children with malaria. This combination is designed to treat uncomplicated Plasmodium falciparum and Plasmodium vivax malaria, which are the two most common types of malaria. The decision to advance to Phase 3 comes after positive results from earlier trials, which showed that the combination was well-tolerated and highly effective. This collaboration between Novartis and MMV is an important step towards developing new and effective treatments for malaria, a disease that continues to affect millions of people worldwide.

Similarly, Lupin, a leading pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for its generic version of Hydroxychloroquine Sulfate Tablets USP, 200 mg. Hydroxychloroquine Sulfate is a medication used to treat and prevent malaria, as well as autoimmune diseases such as lupus and rheumatoid arthritis. The approval of Lupin's generic version provides an affordable alternative to the brand-name drug, helping to improve access to treatment for patients.

Ipca Laboratories, an Indian pharmaceutical company, has been in the news recently as one of its drugs, hydroxychloroquine, is among the three therapies being studied by the World Health Organization (WHO) in the fight against malaria.

Report Scope:

In this report, India Antimalarial Drugs Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• India Antimalarial Drugs Market, By Drug Class:
• Aryl aminoalcohol compounds
• Antifolate compounds
• Artemisinin compounds
• Others
• India Antimalarial Drugs Market, By Mechanism of Action:
• Treatment for Malaria
• Prevention from Malaria
• India Antimalarial Drugs Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India Antimalarial Drugs Market.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order. Single User license will be delivered in PDF format without printing rights